telitacicept   Click here for help

GtoPdb Ligand ID: 11827

Synonyms: RC18 | Tai'ai®
Approved drug Immunopharmacology Ligand
telitacicept is an approved drug (China (2021))
Comment: Telitacicept (RC18) is a recombinant fusion protein that combines the ligand-binding domain of the TACI receptor and the Fc component of human IgG. It was designed to inhibit the signalling of B cell BAFF and APRIL as a mechanism to treat B cell-mediated autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) [2-5].
Peptide Sequence Click here for help
Chemical Modification
Disulfide bridges locations:
intra-TACI: 22-35, 38-50, 42-54, 59-74, 77-88, 81-92
intra-IgG1 Fc: 147-207, 253-311
inter-IgG1 Fc: 112-112', 115-115'
Glycosylation sites: Asn183, Asn183'